FDA Rejects AMT-130 Phase I/II Data for Marketing Application, Recommends Phase III Study
Summary
The FDA has rejected uniQure's Phase I/II data for AMT-130 as insufficient for a marketing application, requiring a full Phase III trial, significantly delaying its lead program. The company also reported an extended cash runway but faced setbacks in other pipeline candidates.
Key Events
-
FDA Rejects AMT-130 Phase I/II Data for Marketing Application
The U.S. Food and Drug Administration (FDA) informed uniQure that its Phase I/II study data for AMT-130, an investigational gene therapy for Huntington's disease, is not sufficient to support a marketing application.
-
FDA Recommends Full Phase III Study
The FDA strongly recommended uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled Phase III study, significantly extending the development timeline and costs for the lead candidate.
-
Extended Cash Runway into Second Half of 2029
The company reported cash, cash equivalents, and current investment securities of $622.5 million as of December 31, 2025, which is expected to fund operations into the second half of 2029, largely due to prior public offerings.
-
Setbacks in Other Pipeline Programs
Dosing in mid- and high-dose cohorts for AMT-191 (Fabry disease) has been paused due to dose-limiting toxicities, and enrollment for AMT-162 (ALS) remains on voluntary pause following a serious adverse event.
Analysis
uniQure N.V. announced a significant regulatory setback for its lead gene therapy candidate, AMT-130 for Huntington's disease. The FDA has stated that the Phase I/II study data, even with positive 36-month results, is insufficient to support a marketing application and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled Phase III study. This decision significantly delays the potential market entry for AMT-130 and will require substantial additional investment in a lengthy clinical trial. While the company reported a strong cash position of $622.5 million, extending its runway into the second half of 2029, this capital will now be needed to fund the newly required Phase III trial. Additionally, other pipeline programs, AMT-191 and AMT-162, reported safety concerns leading to paused dosing or enrollment, adding to the overall negative sentiment regarding the company's clinical progress.
At the time of this filing, QURE was trading at $8.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $962.9M. The 52-week trading range was $7.76 to $71.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.